Transitional Cell Carcinoma Clinical Trial
Official title:
Usage of Vinflunine i.v. (JAVLOR®) for the Treatment of Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium in Adult Patients After Failure of a Cisplatinum-containing Therapy
Documentation of data concerning tolerability and efficacy of the intravenous treatment with vinflunine performed under daily routine conditions in Germany. The trial focusses on tolerability including the assessment of the usage of anti-emetic and anti-obstipative concomitant treatment as well as on the efficacy of the treatment.
n/a
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03296306 -
Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma
|
Phase 3 | |
| Completed |
NCT00880334 -
Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC
|
Phase 2 | |
| Completed |
NCT00216801 -
Relationship of Ochratoxin A to Upper Urologic Cancers
|
N/A | |
| Withdrawn |
NCT04179110 -
Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor
|
Phase 2 | |
| Completed |
NCT00070070 -
Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas
|
Phase 1 | |
| Completed |
NCT00154687 -
Weekly TP-HDFL in the Treatment of Advanced TCC
|
Phase 2 | |
| Completed |
NCT03256877 -
Detecting Transitional Cell Carcinoma From Haematuria
|
||
| Withdrawn |
NCT04006691 -
Efficacy and Safety of UGN-101 in Recurrent Patients
|
Phase 3 | |
| Terminated |
NCT05052372 -
Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib
|
||
| Completed |
NCT00714025 -
A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of Chemotherapy
|
Phase 2 | |
| Terminated |
NCT01310803 -
Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder
|
Phase 3 | |
| Completed |
NCT00623831 -
A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen
|
Phase 1 | |
| Completed |
NCT00173862 -
Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCC
|
Phase 2 | |
| Recruiting |
NCT03896958 -
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
|
||
| Terminated |
NCT01438112 -
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
|
Phase 2/Phase 3 | |
| Completed |
NCT00683059 -
Single Agent Abraxane as Second Line Therapy in Bladder Cancer
|
Phase 2 | |
| Recruiting |
NCT04811846 -
CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood
|
N/A | |
| Not yet recruiting |
NCT04878250 -
Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the Bladder
|
Phase 2 | |
| Completed |
NCT00633789 -
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
|
Phase 2 | |
| Completed |
NCT00612326 -
Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and Staging
|
N/A |